Question to the Department of Health and Social Care:

To ask His Majesty's Government what steps they have taken to ensure availability of Creon for those being treated for pancreatic abnormalities.

The Department is aware of ongoing intermittent supply issues with Creon capsules, a pancreatic enzyme replacement therapy. Supplies of Creon have improved and issues with the lower strength product have resolved, only issues remain for the higher strength Creon product. Specialist importers continue to source unlicensed stock to assist in covering the remaining gap in the market. We continue to work closely with Viatris, the manufacturer of Creon to resolve the issue as soon as possible.

We have widely disseminated comprehensive guidance to healthcare professionals about these supply issues, which provide advice on how to manage patients where there is disruption to supply. This includes serious shortage protocols to limit prescriptions to one month’s supply to ensure Creon remains available for those patients who need it.